Hyperparathyroidism falling

As kidney function continues to decline and the GFR falls less than 60 mL/minute/1.73 m2, phosphorus excretion continues to decrease and calcitriol production decreases, causing PTH levels to begin to rise significantly, leading to secondary hyperparathyroidism (sHPT). The excessive production of PTH leads to hyperplasia of the parathyroid glands, which decreases the sensitivity of the parathyroid glands to serum calcium levels and calcitriol feedback, further promoting sHPT. 

The polypeptide parathormone is released from the parathyroid glands when the plasma Ca2+ level falls. It stimulates osteoclasts to increase bone resorption in the kidneys it promotes calcium reabsorption, while phosphate excretion is enhanced. As blood phosphate concentration diminishes, the tendency of Ca2+ to precipitate as bone mineral decreases. By stimulating the formation of vitamin D hormone, parathormone has an indirect effect on the enteral uptake of Ca2+ and phosphate. In parathormone deficiency, vitamin D can be used as a substitute that, unlike parathormone, is effective orally. Teriparatide is a recombinant shortened parathormone derivative containing the portion required for binding to the receptor. It can be used in the therapy of postmenopausal osteoporosis and promotes bone formation. While this effect seems paradoxical in comparison with hyperparathyroidism, it obviously arises from the special mode of administration the once daily s.c. injection generates a quasi-pulsatile stimulation. Additionally, adequate intake of calcium and vitamin D must be ensured. 

Laboratory findings in rickets and osteomalacia include an increased serum ALP, with other alterations in bone and mineral metabolism dependent on the cause and severity of the disorder. ALP is usually increased because of the increased osteoblastic activity associated with producing unmineralized osteoid. Calcium may be low-normal or low in vitamin D deficiency depending on the severity of the disease. Phosphate may be normal or low, but falls with the development of secondary hyperparathyroidism. The serum calcium and PTH concentrations are usually normal in renal tubular defects of phosphate transport. Vitamin D nutrition may be assessed by the determination of serum 25(OH)D. Renal phosphate defects can be best assessed by determination of the renal phosphate threshold. 

Experiments with everted sacs of rat intestine have shown a fall in the transport of calcium-45 across the intestinal wall after thyroparathyroid-ectomy (D9) and after parathyroidectomy (R2), and it has been suggested that the hormone may promote calcium absorption. It is said that calcium is particularly well absorbed in hyperparathyroidism, but this may be a nonspecific response of the absorptive mechanism to hyper-calcuria (Jl). 

Howard et al. (Hll, H12), who suggested that the rise in plasma phosphate produced by intravenous calcium was due to parathyroid suppression, and that this rise was smaller than normal in hyperparathyroidism. It has since been shown that the effect of intravenous calcium on plasma phosphate is not a measure of parathyroid activity (N5), and this may explain why calcium infusions have tended to fall into disfavor. The fall in urine phosphate which follows calcium infusion does, however, indicate parathyroid suppression (K5, N5). Table 5 shows the effect of a standard calcium infusion on the urinary phosphate/creatinine ratio... 

The principal adverse effect of cinacalcet is hypocalcemia. The drug should not be used if the initial serum calcium is <8.4 mg/dL serum calcium and phosphate concentrations should be measured within one week and PTH should be measured within 4 weeks of therapy initiation. Adynamic bone disease may develop in patients with secondary hyperparathyroidism, so the drug should be discontinued or the dose decreased if the PTH level falls below 150 pg/mL. 

A test for the differential diagnosis of hypercalcaemia. Hydrocortisone or cortisone administration causes a fall in the serum calcium levels in all cases of hypercalcaemia except primary or tertiary hyperparathyroidism. The reasons for this are not well understood. 

Other trials have shown an increased risk of falls and fractures with annual oral administration of high doses of vitamin D. Therefore, supplementation with more frequent, lower doses is preferred. Yet the optimal dosing schedule is unknown and needs further investigation. In order to treat age-associated secondary hyperparathyroidism and to prevent osteoporotic fractures, a daily dose of 1000-1200 mg calcium and 800 lU vitamin D is recommended in elderly or individuals on chronic glucocorticoid therapy. 

---